Table 2.
Maximum Tolerated Dose (MTD) and Acute Toxicity Profile of HH-N25
| Treatment | Dose (mg/kg BW) | Initial BW (g) | Final BW (g) | BW Gain (%) | Clinical Observations (BALB/c Nude Mice) |
|---|---|---|---|---|---|
| 60 | 18.04±2.34 | 19.04±2.24 | 5.55±0.45 | Severe writhing, decreases in spontaneous activity, abdominal tone, and deep respiration 30 min after treatment | |
| HH-N25 (NSC772867) | 30 | 19.04±1.15 | 19.52±1.24 | 2.45±0.02 | Severe writhing, decreases in spontaneous activity, abdominal tone, and deep respiration 30 min after treatment |
| 20 | 24.03±0.35 | 24.95±0.24 | 3.68±0.34 | Moderate writhing, decreases in spontaneous activity and deep respiration 30 min after treatment | |
| 10 | 20.04±0.67 | 21.05±0.35 | 4.79±0.53 | Slight writhing, decreases in spontaneous activity and deep respiration | |
| 5 | 21.03±0.90 | 21.98±0.24 | 4.32±0.93 | None |
Abbreviation: BW, body weight.